Market Closed -
Deutsche Boerse AG
09:59:57 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
10.42
EUR
|
-0.38%
|
|
+1.36%
|
-8.68%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,244
|
2,510
|
2,509
|
2,308
|
-
|
-
|
Enterprise Value (EV)
1 |
6,847
|
4,085
|
2,509
|
3,880
|
3,919
|
3,759
|
P/E ratio
|
8.39
x
|
16.6
x
|
27.2
x
|
25.6
x
|
33.9
x
|
-
|
Yield
|
1.4%
|
2.91%
|
-
|
0.86%
|
2.1%
|
3.14%
|
Capitalization / Revenue
|
1.39
x
|
0.77
x
|
0.95
x
|
0.79
x
|
0.74
x
|
0.7
x
|
EV / Revenue
|
1.82
x
|
1.26
x
|
0.95
x
|
1.33
x
|
1.26
x
|
1.13
x
|
EV / EBITDA
|
5.66
x
|
5.43
x
|
5.73
x
|
6.98
x
|
6.38
x
|
5.11
x
|
EV / FCF
|
7.89
x
|
8.67
x
|
-
|
40.7
x
|
30.1
x
|
-
|
FCF Yield
|
12.7%
|
11.5%
|
-
|
2.46%
|
3.32%
|
-
|
Price to Book
|
2.32
x
|
1.07
x
|
-
|
0.97
x
|
0.89
x
|
0.8
x
|
Nbr of stocks (in thousands)
|
222,222
|
221,562
|
219,707
|
219,775
|
-
|
-
|
Reference price
2 |
23.60
|
11.33
|
11.42
|
10.50
|
10.50
|
10.50
|
Announcement Date
|
3/16/22
|
3/16/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,765
|
3,251
|
2,635
|
2,914
|
3,102
|
3,314
|
EBITDA
1 |
-
|
1,210
|
753
|
437.9
|
556
|
614
|
735
|
EBIT
1 |
-
|
996.1
|
508
|
194.2
|
351
|
410
|
437
|
Operating Margin
|
-
|
26.46%
|
15.63%
|
7.37%
|
12.05%
|
13.22%
|
13.19%
|
Earnings before Tax (EBT)
1 |
-
|
805.6
|
283
|
143
|
273
|
329
|
-
|
Net income
1 |
257.6
|
624.8
|
151
|
92.27
|
91.4
|
69.2
|
253
|
Net margin
|
-
|
16.6%
|
4.64%
|
3.5%
|
3.14%
|
2.23%
|
7.63%
|
EPS
2 |
-
|
2.811
|
0.6815
|
0.4200
|
0.4100
|
0.3100
|
-
|
Free Cash Flow
1 |
-
|
867.2
|
471.4
|
-
|
95.3
|
130.2
|
-
|
FCF margin
|
-
|
23.03%
|
14.5%
|
-
|
3.27%
|
4.2%
|
-
|
FCF Conversion (EBITDA)
|
-
|
71.68%
|
62.6%
|
-
|
17.14%
|
21.21%
|
-
|
FCF Conversion (Net income)
|
-
|
138.8%
|
312.15%
|
-
|
104.27%
|
188.15%
|
-
|
Dividend per Share
2 |
-
|
0.3300
|
0.3300
|
-
|
0.0900
|
0.2200
|
0.3300
|
Announcement Date
|
4/20/21
|
3/16/22
|
3/16/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
992.6
|
1,061
|
790.4
|
1,851
|
697.9
|
702.4
|
669.7
|
EBITDA
1 |
-
|
356.9
|
171.1
|
528
|
135
|
118.5
|
113.5
|
EBIT
|
-
|
300.1
|
110.7
|
410.8
|
75.8
|
60.5
|
-
|
Operating Margin
|
-
|
28.28%
|
14%
|
22.19%
|
10.86%
|
8.61%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/22
|
5/12/22
|
8/11/22
|
8/11/22
|
11/10/22
|
5/12/23
|
8/9/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
1,602
|
1,575
|
-
|
1,572
|
1,611
|
1,451
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.324
x
|
2.092
x
|
-
|
2.827
x
|
2.624
x
|
1.974
x
|
Free Cash Flow
1 |
-
|
867
|
471
|
-
|
95.3
|
130
|
-
|
ROE (net income / shareholders' equity)
|
-
|
39%
|
14.9%
|
-
|
3.9%
|
2.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
12.6%
|
6.33%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
4,949
|
2,386
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
10.20
|
10.60
|
-
|
10.80
|
11.70
|
13.20
|
Cash Flow per Share
2 |
-
|
4.700
|
2.840
|
-
|
1.560
|
1.640
|
1.790
|
Capex
1 |
-
|
144
|
158
|
-
|
277
|
279
|
-
|
Capex / Sales
|
-
|
3.84%
|
4.87%
|
-
|
9.5%
|
8.99%
|
-
|
Announcement Date
|
4/20/21
|
3/16/22
|
3/16/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
10.5
EUR Average target price
14.5
EUR Spread / Average Target +38.10% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.89% | 8.25B | | +39.20% | 3.57B | | -39.11% | 2.46B | | -7.35% | 2.38B | | -12.61% | 1.81B | | -19.01% | 1.55B | | -40.66% | 1.21B | | +7.56% | 1.11B | | -15.34% | 1.03B |
Medical & Diagnostic Laboratories
|